Amneal's CREXONT Shows Strong, Consistent Benefits in Full Phase 4 Parkinson's Study
AMRX sits 96% above its 52-week low of $7.07.
Summary
Amneal announced positive interim results from the full study population (n=214) of its Phase 4 ELEVATE-PD study for CREXONT in Parkinson's disease. This update reinforces previously reported benefits, showing clinically meaningful increases in "Good On" time (up to +3.33 hours) and reductions in "Off" time (up to -3.20 hours) across all patient groups. For patients switching from RYTARY, continuous "Good On" intervals nearly doubled. This robust data strengthens the commercial profile and differentiation of CREXONT, a key next-generation product for the company.
At the time of this announcement, AMRX was trading at $13.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $7.07 to $15.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.